Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Switzerland.
Global Medical Affairs, Almirall S.A., Barcelona, Spain.
Neurodegener Dis Manag. 2022 Jun;12(3):141-154. doi: 10.2217/nmt-2022-0002. Epub 2022 Apr 4.
Effective symptomatic management of multiple sclerosis (MS) spasticity remains an unmet need for many patients. The second-line option nabiximols is the most widely investigated of the noninvasive antispasticity medications in this patient population. Clinical evidence accumulated with nabiximols since it was first approved in Europe in 2010 suggests that about 40% of initial responders (i.e., those with ≥20% improvement in their baseline 0-10 Numerical Rating Scale score) may expect to achieve clinically meaningful (≥30% Numerical Rating Scale response) and durable symptomatic improvement in MS spasticity. During 10 years' routine use of nabiximols, no new safety signals have emerged. Nabiximols-associated improvement in MS spasticity-related symptoms such as pain and sleep disruption suggests a need to track possible therapeutic effects beyond muscle tone control.
多发性硬化症（MS）痉挛的有效症状管理仍然是许多患者未满足的需求。纳比西莫司是二线选择，是该患者人群中研究最广泛的非侵入性抗痉挛药物。自 2010 年首次在欧洲获得批准以来，纳比西莫司积累的临床证据表明，约 40%的初始应答者（即基线 0-10 数字评定量表评分改善≥20%的患者）可能期望在 MS 痉挛中获得有临床意义的（≥30%数字评定量表应答）和持久的症状改善。在纳比西莫司 10 年的常规使用过程中，没有出现新的安全信号。纳比西莫司改善 MS 痉挛相关症状，如疼痛和睡眠障碍，这表明需要跟踪除肌肉张力控制之外的可能治疗效果。
